Colorectal Cancer

SAN FRANCISCO—For patients with colorectal cancer (CRC), advances in molecular profiling have led to an ex - plosion in novel agents specific for targets above and beyond the epidermal growth factor receptor (EGFR). Joseph Tabernero, MD, director of clinical research at Vall d’Hebron Institute of Oncology in Barcelona, Spain, previewed the future of treatment for CRC at the 2011 Gastrointestinal Cancers Symposium.

Pharmacogenomics is the study of the role of inherited and acquired genetic variation in drug response.1 A focus of research in recent years on genome-wide association studies ultimately may help identify patient- and/or cancer-specific biomarkers that will facilitate optimization of drug therapy including guiding drug selection, dose, and treatment duration.2 The identification of the role of KRASmutations in select patients with colorectal cancer (CRC) who are candidates for epidermal growth factor receptor (EGFR) in hibitors is one example of the clinical a

SALT LAKE CITY—Reliable tests are sorely needed to help determine the best dose regimen before chemotherapy to minimize toxicities for patients with metastatic colon cancer, according to a talk given at the annual meeting of the Hematology/Oncology Pharmacy Association.

For patients with a past history or family history of colorectal cancer, annual fecal immunochemical tests (FITs) detect neoplasias sooner than scheduled 10-year colonoscopies, according to a new study published in the December issue of Gastroenterology. For patients with FIT-positive results, diagnosis was made sooner by 25 months for cancer and by 24 months for advanced adenomas.
Page 2 of 2
Results 11 - 14 of 14